KRAS and neoplasm: Furthermore, patients who previously used HRT and had the KRAS-variant tended to be diagnosed with higher grade tumors compared to non-variant patients who had previously been on HRT (2.33 vs. 1.98, p = 0.029), indicating that overall the KRAS-variant is predictive of an aggressive tumor biology in patients with low estrogen or experiencing abrupt estrogen withdrawal (Table 3).